Table 1.
Clinical characteristics of study population
| Group 1 patients with VT/VF during follow-up (n = 29) | Group 2 patients without VT/VF during follow-up (n = 18) | p | |
|---|---|---|---|
| Age (years) | 66.38 ± 8.81 | 68.50 ± 12.23 | NS |
| Sex (M = 1) n (%) | 24 (82 %) | 12 (67 %) | NS |
| BMI | 28.02 ± 5.54 | 27.54 ± 4.26 | NS |
| Ischemic etiology, n (%) | 15 (52 %) | 14 (78 %) | NS |
| Arterial hypertension, n (%) | 11 (38 %) | 12 (67 %) | NS |
| Cardiomyopathy, n (%) | 23 (79 %) | 8 (44 %) | 0.014 |
| DM total, n (%) | 11 (38 %) | 5 (28 %) | NS |
| Hyperlipidemia, n (%) | 7 (24 %) | 5 (28 %) | NS |
| Atrial fibrillation, n (%) | 9 (31 %) | 5 (28 %) | NS |
| QRS duration (ms) | 161.59 ± 32.34 | 179.94 ± 35.42 | NS |
| Mean blood pressure (mmHg) | 96.94 ± 10.10 | 100.97 ± 12.26 | NS |
| K (mmol/l) | 4.51 ± 0.49 | 4.44 ± 0.40 | NS |
| Pre-implantation PCI, n (%) | 10 (34 %) | 6 (33 %) | NS |
| Beta-blocker, n (%) | 25 (86 %) | 16 (89 %) | NS |
| ACEI/ARB, n (%) | 24 (83 %) | 15 (83 %) | NS |
ACEI/ARB angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, BMI body mass index, DM diabetes mellitus, K potassium, NS not significant, PCI percutaneous coronary intervention, VF ventricular fibrillation, VT ventricular tachycardia